Bradykinin Antagonist Dimer, CU201, Inhibits the Growth of Human Lung Cancer Cell Lines in Vitro and in Vivo and Produces Synergistic Growth Inhibition in Combination with Other Antitumor Agents

• Published in: Clinical cancer research 2002-05, Vol.8 (5), p.1280-1287
• Main Authors: CHAN, Daniel C, GERA, Lajos, STEWART, John M, HELFRICH, Barbara, ZHAO, Tom Limin, WAN YONG FENG, CHAN, Kenneth K, COVEY, Joseph M, BUNN, Paul A
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic agents; Antineoplastic Agents - pharmacology; Area Under Curve; Biological and medical sciences; Bradykinin - analogs & derivatives; Bradykinin - chemistry; Bradykinin - pharmacology; Bradykinin Receptor Antagonists; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - metabolism; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Small Cell - drug therapy; Carcinoma, Small Cell - metabolism; Carcinoma, Small Cell - pathology; Cell Division - drug effects; Chemotherapy; Cisplatin - pharmacology; Dimerization; Doxorubicin - pharmacology; Drug Synergism; Drug Therapy, Combination; Etoposide - pharmacology; Humans; Infusion Pumps; Injections, Intralesional; Injections, Intraperitoneal; Injections, Subcutaneous; Lung Neoplasms - drug therapy; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Medical sciences; Mice; Mice, Nude; Neoplasm Transplantation; Oligopeptides - pharmacokinetics; Oligopeptides - pharmacology; Paclitaxel - pharmacology; Pharmacology. Drug treatments; Quinazolines - pharmacology; Time Factors; Tumor Cells, Cultured - drug effects; Vinblastine - analogs & derivatives; Vinblastine - pharmacology; Xenograft Model Antitumor Assays
• ISSN: 1078-0432; 1557-3265

Small cell lung cancers (SCLCs), many non-SCLCs, andother cancers have neuroendocrine features, including paracrineand autocrine growth stimulation by various neuropeptides. Interference with this pathway is an attractive target for novel therapies. We developed a novel bradykinin antagonist dimer, CU201 (B9870), that acts as a “biased agonist” for neuropeptides by blocking G αq signaling and activating G α12,13 signaling. CU201 induced apoptosis and complete growth inhibition in various lung cancer and other cancer cell lines. CU201 was 10-fold more potent than substance P derivatives and was stable in serum for >7 days. In this study, we evaluated the ability of CU201 to produce additive or synergistic growth inhibition in combination with various antitumor agents used in lung cancer therapy. We found that CU201 produced additive or synergistic growth inhibition when combined with doxorubicin, etoposide, cisplatin, vinorelbine, and paclitaxel for SCLC lines and with paclitaxel and ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, for non-SCLC cell lines. Pharmacokinetic parameters associated with the i.v. administration of CU201 were evaluated in normal mice, and the effects of CU201 on the growth of human lung cancer xenografts were evaluated in athymic nude mice. In CD2F1 mice given an i.v. bolus infusion of 5 mg/kg, the c max was 5773 ng/ml (5 μ m ), and the decay was biexponential. When fitted to a two-compartment model, the t 1/2α was 14.4 min, and the t 1/2β was 44.3 h, indicating a long terminal half-life consistent with the prolonged in vitro effects. CU201 inhibited the growth of human lung cancers in athymic nude mice by the intratumoral, s.c., and i.p. routes at a dose of 5 mg/kg/day. This dose is >10-fold less than the dose of substance P derivatives used to inhibit SCLC xenografts in nude mice. We conclude that CU201 should undergo further preclinical toxicology studies in its development as a novel targeted therapy for the treatment of lung cancers with neuroendocrine features. These studies are in progress through the NCI RAID mechanism.